GSA Capital Partners’s Stemline Therapeutics, Inc. STML Stock Holding History

GSA Capital Partners’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-19,981	Closed	-$97K	–	1323
2020 Q1	$97K	Buy	+19,981	New	+$130K	0.02%	906
2019 Q4	–	Sell	-46,033	Closed	-$479K	–	1866
2019 Q3	$479K	Buy	+46,033	New	+$602K	0.06%	580

GSA Capital Partners's STML Position: Q2 2020 in Review

GSA Capital Partners sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 19,981 shares — an estimated $97K sold.

GSA Capital Partners first reported a position in STML in Q3 2019 and held it in 2 quarters. The position peaked at $479K in Q3 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

GSA Capital Partners reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
GSA Capital Partners sold 19,981 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $97K.
GSA Capital Partners first reported a position in Stemline Therapeutics, Inc. in Q3 2019 and held it in 2 quarters.
GSA Capital Partners's Stemline Therapeutics, Inc. position peaked at $479K in Q3 2019.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on GSA Capital Partners's 13F filing for Q2 2020, filed 11 Aug 2020.